2006
Physical activity in a cohort of HIV-positive and HIV-negative injection drug users
Smit E, Crespo C, Semba R, Jaworowicz D, Vlahov D, Ricketts E, Ramirez-Marrero F, Tang A. Physical activity in a cohort of HIV-positive and HIV-negative injection drug users. AIDS Care 2006, 18: 1040-1045. PMID: 17012097, DOI: 10.1080/09540120600580926.Peer-Reviewed Original ResearchConceptsInjection drug usersHIV-positive participantsHIV-positive injection drug usersInjection drug useHIV-negativeVigorous activityPhysical activityDrug usersDrug usePaffenbarger Physical Activity QuestionnaireRecent injection drug usersHIV-negative injection drug usersIntravenous Experience cohortActive antiretroviral therapyCohort of HIVHIV-negative participantsPhysical Activity QuestionnairePhysical activity levelsAntiretroviral therapyHIV infectionViral loadHIV treatmentActivity QuestionnaireAnthropometric measurementsEnergy expenditure
2005
Injection Drug Use Is an Independent Risk Factor for Iron Deficiency and Iron Deficiency Anemia Among HIV-Seropositive and HIV-Seronegative Women
Dancheck B, Tang A, Thomas A, Smit E, Vlahov D, Semba R. Injection Drug Use Is an Independent Risk Factor for Iron Deficiency and Iron Deficiency Anemia Among HIV-Seropositive and HIV-Seronegative Women. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2005, 40: 198-201. PMID: 16186738, DOI: 10.1097/01.qai.0000165909.12333.07.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnemia, Iron-DeficiencyCase-Control StudiesFemaleHIV SeronegativityHIV SeropositivityHumansMiddle AgedSubstance Abuse, IntravenousConceptsInjection drug useIron deficiency anemiaHepatitis C virus statusFemale injection drug usersC virus statusInjection drug usersDeficiency anemiaDrug useIron deficiencyRisk factorsVirus statusDrug usersMultivariate analysisInjection drug use historyCD4 lymphocyte countHIV-seronegative womenIndependent risk factorHIV-positive womenCross-sectional studyFurther longitudinal studiesNatural history studiesIntravenous Experience (ALIVE) studyDrug use historyHIV-seropositiveLymphocyte countThe relationship between non‐injection drug use behaviors on progression to AIDS and death in a cohort of HIV seropositive women in the era of highly active antiretroviral therapy use
Kapadia F, Cook J, Cohen M, Sohler N, Kovacs A, Greenblatt R, Choudhary I, Vlahov D. The relationship between non‐injection drug use behaviors on progression to AIDS and death in a cohort of HIV seropositive women in the era of highly active antiretroviral therapy use. Addiction 2005, 100: 990-1002. PMID: 15955015, PMCID: PMC3128378, DOI: 10.1111/j.1360-0443.2005.01098.x.Peer-Reviewed Original ResearchConceptsNon-injection drug useWomen's Interagency HIV StudyHIV progressionMultivariate analysisActive antiretroviral therapy (HAART) eraActive antiretroviral therapy (HAART) useMultivariate Cox proportional hazardsAntiretroviral therapy eraAntiretroviral therapy useFormer usersHIV-seropositive womenProspective cohort studyCells/Cox proportional hazardsDrug use behaviorsUse of stimulantsCause deathHAART initiationHAART utilizationTherapy eraCause mortalityHAART useSeropositive womenAIDS eventsCohort study
2003
Effects of CCR5-Δ32 and CCR2-64I alleles on HIV-1 disease progression
Mulherin S, O'Brien T, Ioannidis J, Goedert J, Buchbinder S, Coutinho R, Jamieson B, Meyer L, Michael N, Pantaleo G, Rizzardi G, Schuitemaker H, Sheppard H, Theodorou I, Vlahov D, Rosenberg P. Effects of CCR5-Δ32 and CCR2-64I alleles on HIV-1 disease progression. AIDS 2003, 17: 377-387. PMID: 12556692, DOI: 10.1097/00002030-200302140-00012.Peer-Reviewed Original ResearchConceptsHIV-1 disease progressionHIV-1 seroconvertersCCR5-Delta32CCR2-64ICourse of infectionDisease progressionLower riskChemokine receptor gene polymorphismsCox proportional hazards modelHIV-1 infectionIndividual patient dataCCR2-64I alleleProportional hazards modelReceptor gene polymorphismsCCR2-64I.Disease courseSurvival benefitHazards modelGene polymorphismsCCR5-Δ32Significant protectionAIDSPatient dataInfectionSeroconverters
2001
Evidence of rodent-associated Bartonella and Rickettsia infections among intravenous drug users from Central and East Harlem, New York City.
Comer J, Diaz T, Vlahov D, Monterroso E, Childs J. Evidence of rodent-associated Bartonella and Rickettsia infections among intravenous drug users from Central and East Harlem, New York City. American Journal Of Tropical Medicine And Hygiene 2001, 65: 855-60. PMID: 11791987, DOI: 10.4269/ajtmh.2001.65.855.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAnimalsAntibodies, BacterialBartonellaBartonella InfectionsCohort StudiesCross ReactionsFemaleFluorescent Antibody Technique, IndirectHIV SeropositivityHumansMaleNew York CityPrevalenceRatsRickettsiaRickettsia InfectionsSubstance Abuse, IntravenousSurveys and QuestionnairesUrban HealthConceptsInjection drug usersDrug usersGroup rickettsiaeSerum samplesIntravenous drug usersCross-adsorption studiesEast HarlemR. akari infectionPrimary etiologic agentTyphus group rickettsiaeFever group rickettsiaeIDU populationHigh prevalenceEtiologic agentNew York CityRickettsia akariBartonella henselaeAntigenTesting panelsRickettsia typhiB. henselaeBartonella quintanaR. rickettsiiRickettsia infectionR. akariSexual and drug risk-related behaviours after initiating highly active antiretroviral therapy among injection drug users
Vlahov D, Safaien M, Lai S, Strathdee S, Johnson L, Sterling T, Celentano D. Sexual and drug risk-related behaviours after initiating highly active antiretroviral therapy among injection drug users. AIDS 2001, 15: 2311-2316. PMID: 11698705, DOI: 10.1097/00002030-200111230-00013.Peer-Reviewed Original ResearchConceptsInjection drug usersHIV-seropositive injection drug usersActive antiretroviral therapyUntreated groupHigh-risk behaviorsAntiretroviral therapyConsecutive visitsDrug usersRisk behaviorsInitiation of HAARTCD4 cell countOngoing prospective studySemi-annual interviewsLinear growth curve analysesHAART useMedian ageMedication useProspective studyNeedle sharingHAARTCell countUnprotected sexRisk-related behaviorsCurve analysisStudy periodAccess to medical care and service utilization among injection drug users with HIV/AIDS
Knowlton A, Hoover D, Chung S, Celentano D, Vlahov D, Latkin C. Access to medical care and service utilization among injection drug users with HIV/AIDS. Drug And Alcohol Dependence 2001, 64: 55-62. PMID: 11470341, DOI: 10.1016/s0376-8716(00)00228-3.Peer-Reviewed Original ResearchConceptsCase managementService utilizationDrug treatmentCurrent drug injectorsOutpatient service usePhysical functioning limitationsEmergency room useInjection drug usersCurrent drug useDaily alcohol useHIV/AIDSSubstance abuse treatmentHIV careAIDS diagnosisOutpatient careFunctioning limitationsDrug injectorsOutpatient servicesService useDrug usersDrug useMedical careAbuse treatmentHospital servicesAlcohol useThe difference between men and women drug users in seroconversion risk factors.
Strathdee S, Galai N, Safaiean M, Celentano D, Vlahov D, Johnson L, Nelson K. The difference between men and women drug users in seroconversion risk factors. SIDA Ahora 2001, 25-6. PMID: 11681272.Peer-Reviewed Original ResearchSex Differences in Risk Factors for HIV Seroconversion Among Injection Drug Users: A 10-Year Perspective
Strathdee S, Galai N, Safaiean M, Celentano D, Vlahov D, Johnson L, Nelson K. Sex Differences in Risk Factors for HIV Seroconversion Among Injection Drug Users: A 10-Year Perspective. JAMA Internal Medicine 2001, 161: 1281-1288. PMID: 11371255, DOI: 10.1001/archinte.161.10.1281.Peer-Reviewed Original ResearchConceptsInjection drug usersIncidence of HIVHIV seroconversionRisk factorsProspective studyDrug usersHigh-risk heterosexual activityHuman immunodeficiency virus interventionsHIV-negative injection drug usersHuman immunodeficiency virus (HIV) infectionFemale injection drug usersImmunodeficiency virus infectionInjection drug useDrug-related risksHomosexual activityTime-dependent covariatesHIV testMedian agePerson yearsDaily injectionsNeedle sharingCocaine injectionHIV riskVirus infectionSeroconversionHuman Immunodeficiency Virus Seroconversion and Evolution of the Hepatitis C Virus Quasispecies
Mao Q, Ray S, Laeyendecker O, Ticehurst J, Strathdee S, Vlahov D, Thomas D. Human Immunodeficiency Virus Seroconversion and Evolution of the Hepatitis C Virus Quasispecies. Journal Of Virology 2001, 75: 3259-3267. PMID: 11238852, PMCID: PMC114119, DOI: 10.1128/jvi.75.7.3259-3267.2001.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusHCV quasispeciesHypervariable region 1HIV seroconversionChronic hepatitis C virus (HCV) infectionE2 hypervariable region 1Hepatitis C virus infectionHuman immunodeficiency virus (HIV) seroconversionRapid HIV disease progressionHepatitis C virus quasispeciesHIV infection altersHIV-associated diseaseChronic HCV infectionC virus infectionHIV disease progressionHCV infectionHCV RNASerum levelsLiver diseaseImmunodeficiency virusDisease progressionRapid progressionVirus infectionNumber of subjectsHCV sequencesMortality, CD4 Cell Count Decline, and Depressive Symptoms Among HIV-Seropositive Women: Longitudinal Analysis From the HIV Epidemiology Research Study
Ickovics J, Hamburger M, Vlahov D, Schoenbaum E, Schuman P, Boland R, Moore J, Group F. Mortality, CD4 Cell Count Decline, and Depressive Symptoms Among HIV-Seropositive Women: Longitudinal Analysis From the HIV Epidemiology Research Study. JAMA 2001, 285: 1466-1474. PMID: 11255423, DOI: 10.1001/jama.285.11.1466.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virusChronic depressive symptomsCD4 cell countHIV-seropositive womenTreatment of depressionDepressive symptomsCell countDisease progressionBaseline CD4 cell countCD4 cell count declineHIV Epidemiologic Research StudyCell count declineCD4 lymphocyte countBaseline viral loadEpidemiologic Studies Depression ScaleHIV disease progressionHIV Epidemiology Research StudyLongitudinal cohort studyEpidemiologic research studiesImpact of depressionAcademic medical centerSelf-reported CenterCohort studyLymphocyte countCount decline
2000
Prevention of HIV Infection in Street-Recruited Injection Drug Users
Monterroso E, Hamburger M, Vlahov D, Jarlais D, Ouellet L, Altice F, Byers R, Kerndt P, Watters J, Bowser B, Fernando D, Holmberg S. Prevention of HIV Infection in Street-Recruited Injection Drug Users. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 25: 63-70. DOI: 10.1097/00126334-200009010-00009.Peer-Reviewed Original ResearchConceptsInjection drug usersDrug usersHIV infectionInitial serum specimensLarge multicity studyHIV prevention strategiesHIV infection riskHIV prevention programsSyringe exchange programsDrug treatment programsUse of needlesNew AIDSHIV acquisitionHIV serostatusHIV casesPrevention strategiesSerum specimensSex partnersInfection ratePrevention programsTreatment programInfection riskStandard questionnaireHIVMultivariate modelPrevention of HIV Infection in Street-Recruited Injection Drug Users
Monterroso E, Hamburger M, Vlahov D, Jarlais D, Ouellet L, Altice F, Byers R, Kerndt P, Watters J, Bowser B, Fernando M, Holmberg S. Prevention of HIV Infection in Street-Recruited Injection Drug Users. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2000, 25: 63-70. PMID: 11064506, DOI: 10.1097/00042560-200009010-00009.Peer-Reviewed Original ResearchConceptsInjection drug usersDrug usersHIV infectionInitial serum specimensLarge multicity studyHIV prevention strategiesHIV infection riskHIV prevention programsSyringe exchange programsDrug treatment programsUse of needlesNew AIDSHIV acquisitionHIV serostatusHIV casesPrevention strategiesSerum specimensSex partnersInfection ratePrevention programsTreatment programInfection riskStandard questionnaireHIVMultivariate modelCorrelates of enrollment in methadone maintenance treatment programs differ by HIV-serostatus
Shah N, Celentano D, Vlahov D, Stambolis V, Johnson L, Nelson K, Strathdee S. Correlates of enrollment in methadone maintenance treatment programs differ by HIV-serostatus. AIDS 2000, 14: 2035-2043. PMID: 10997409, DOI: 10.1097/00002030-200009080-00020.Peer-Reviewed Original ResearchMeSH KeywordsAdultBaltimoreCohort StudiesFemaleHealth Services AccessibilityHIV AntibodiesHIV InfectionsHIV SeronegativityHIV SeropositivityHumansMaleMethadoneMiddle AgedNeedle-Exchange ProgramsProspective StudiesRisk-TakingSocioeconomic FactorsSubstance Abuse Treatment CentersSubstance Abuse, IntravenousConceptsMethadone maintenance treatment programInjection drug usersMaintenance treatment programNeedle exchange programsHIV serostatusHIV-seronegative injection drug usersSeronegative injection drug usersHIV-negative injection drug usersTreatment programHIV-seropositive participantsHealth care providersTreatment slotsNeedle exchange program participantsAfrican AmericansHIV testProspective cohortCare providersDrug usersProgram attendanceOlder ageCertain subgroupsVulnerable populationsSimilar proportionsBehavioral factorsEnrollmentCervical Neoplasia and Repeated Positivity of Human Papillomavirus Infection In Human Immunodeficiency Virus-seropositive and -seronegative Women
Ahdieh L, Munoz A, Vlahov D, Trimble C, Timpson L, Shah K. Cervical Neoplasia and Repeated Positivity of Human Papillomavirus Infection In Human Immunodeficiency Virus-seropositive and -seronegative Women. American Journal Of Epidemiology 2000, 151: 1148-1157. PMID: 10905527, DOI: 10.1093/oxfordjournals.aje.a010165.Peer-Reviewed Original ResearchMeSH KeywordsAdultAntiviral AgentsCD4 Lymphocyte CountFemaleHIV InfectionsHIV SeronegativityHIV SeropositivityHumansImmunosuppression TherapyIncidenceLongitudinal StudiesPapillomaviridaePapillomavirus InfectionsRisk AssessmentSurvival AnalysisTumor Virus InfectionsUterine Cervical DysplasiaUterine Cervical NeoplasmsConceptsCervical intraepithelial neoplasiaHuman papillomavirus infectionHPV positivityHPV clearancePapillomavirus infectionHIV infectionBiopsy-confirmed cervical intraepithelial neoplasiaAssociation of HIVPotent antiretroviral therapyCervicovaginal lavage specimensHuman immunodeficiency virusCells/Reversal of immunosuppressionPolymerase chain reaction-based assaySeronegative womenAntiretroviral therapyHIV- womenHPV resultsHIV- participantsHPV DNACervical neoplasiaHIV serostatusIntraepithelial neoplasiaImmunodeficiency virusRelated immunosuppression
1999
Prevalence of Lower Genital Tract Infections Among Human Immunodeficiency Virus (HIV)—Seropositive and High-Risk HIV-Seronegative Women
Cu-Uvin S, Hogan J, Warren D, Klein R, Peipert J, Schuman P, Holmberg S, Anderson J, Schoenbaum E, Vlahov D, Mayer K, Group F. Prevalence of Lower Genital Tract Infections Among Human Immunodeficiency Virus (HIV)—Seropositive and High-Risk HIV-Seronegative Women. Clinical Infectious Diseases 1999, 29: 1145-1150. PMID: 10524955, DOI: 10.1086/313434.Peer-Reviewed Original ResearchConceptsHIV-seronegative womenGenital tract infectionLower genital tract infectionHuman immunodeficiency virusTract infectionsBacterial vaginosisImmunodeficiency virusHigh-risk HIV-seronegative womenLower Genital Tract InfectionsRisk HIV-seronegative womenHuman papilloma virus infectionHIV-seropositive womenPapilloma virus infectionHigh-risk womenNeisseria gonorrhoeae infectionChlamydia trachomatis infectionHIV Epidemiology Research StudySimilar HIVSeropositive womenGonorrhoeae infectionBaseline visitTrachomatis infectionCandidal vaginitisVirus infectionInfectionThe Effect of Drug-Injection Behavior on Genetic Evolution of HIV-1
Carneiro M, Yu X, Lyles C, Templeton A, Weisstein A, Safaeian M, Farzadegan H, Vlahov D, Markham R. The Effect of Drug-Injection Behavior on Genetic Evolution of HIV-1. The Journal Of Infectious Diseases 1999, 180: 1025-1032. PMID: 10479127, DOI: 10.1086/315044.Peer-Reviewed Original ResearchLongitudinal Human Immunodeficiency Virus Type 1 Load in the Italian Seroconversion Study: Correlates and Temporal Trends of Virus Load
Lyles C, Dorrucci M, Vlahov D, Pezzotti P, Angarano G, Sinicco A, Alberici F, Alcorn T, Vella S, Rezza G. Longitudinal Human Immunodeficiency Virus Type 1 Load in the Italian Seroconversion Study: Correlates and Temporal Trends of Virus Load. The Journal Of Infectious Diseases 1999, 180: 1018-1024. PMID: 10479126, DOI: 10.1086/314980.Peer-Reviewed Original ResearchConceptsHIV-1 loadVirus loadHuman immunodeficiency virus type 1 (HIV-1) loadHuman immunodeficiency virus type 1 (HIV-1) seroconvertersCD4 cells/microL.Low CD4 cell countsItalian Seroconversion StudyCD4 cell countCells/microL.Injection drug useCourse of diseaseReverse transcriptase-polymerase chain reactionHigh virus loadTranscriptase-polymerase chain reactionClinical AIDSMale sexProspective studyDisease progressionSeroconversion StudyCell countDrug useSustained increaseSeroconversionAIDSFrozen serumSelf-Reported Bacterial Infections Among Women with or at Risk for Human Immunodeficiency Virus Infection
Flanigan T, Hogan J, Smith D, Schoenbaum E, Vlahov D, Schuman P, Mayer K. Self-Reported Bacterial Infections Among Women with or at Risk for Human Immunodeficiency Virus Infection. Clinical Infectious Diseases 1999, 29: 608-612. PMID: 10530455, DOI: 10.1086/598641.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus (HIV) infectionCD4 cell countImmunodeficiency virus infectionBacterial infectionsRecent pneumoniaVirus infectionCell countHIV-negative womenHIV-seropositive womenUrinary tract infectionInjection drug useLogistic regression analysisSelf-reported pneumoniaCross-sectional analysisSeronegative womenTract infectionsHIV infectionDrug useLifetime historyInfectionPneumoniaMajor causeWomenRegression analysisCell categoriesSex Differences in Longitudinal Human Immunodeficiency Virus Type 1 RNA Levels among Seroconverters
Sterling T, Lyles C, Vlahov D, Astemborski J, Margolick J, Quinn T. Sex Differences in Longitudinal Human Immunodeficiency Virus Type 1 RNA Levels among Seroconverters. The Journal Of Infectious Diseases 1999, 180: 666-672. PMID: 10438353, DOI: 10.1086/314967.Peer-Reviewed Original ResearchConceptsHuman immunodeficiency virus type 1 RNA levelsHIV-1 seroconvertersSex differencesCopies/mLHIV-1 pathogenesisInjection drug usersCase-control studyTime of seroconversionCross-sectional studyCourse of infectionMale patientsRapid progressorsFemale patientsCopies/Drug usersMale controlsVirus levelsPatientsRNA levelsSeroconvertersWomenMenNonprogressorsSeroconversionProgressors